{"entity":{"id":"nct06992609","kind":"trial","name":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","aka":[],"tldr":"A phase 3 trial of Durvalumab in small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. is a phase 3 interventional study registered as NCT06992609 by AstraZeneca, with 68 participants enrolled, started 2025-09-15 and due to reach its primary completion in 2029-06-30. Interventions recorded: Durvalumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06992609","url":"https://clinicaltrials.gov/study/NCT06992609"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06992609","phase":"3","setting":"A Phase IIIb Study of Durvalumab as Consolidation Treatment for Patients Diagnosed With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Definitive Concurrent or Sequential Platinum-based Chemoradiation Therapy in Spain (ALBORAN).","sponsor":"AstraZeneca","enrolled":68,"outcomes":[]},"route":"/trials/nct06992609/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}